Skip to content
Open access

Estimating and Projecting Efficacy of Monoclonal Antibodies Against Respiratory Syncytial Virus Beyond Clinical Trial Periods

Aug 2026 · Vaccines · Vol 14, pp. 737 · 0 citations · 12 references
Medicine

TL;DR

Both RSV mAbs were projected to provide some level of protection throughout the first year following administration, with broadly similar levels of protection.

Abstract

Background: Clinical trials of respiratory syncytial virus (RSV) monoclonal antibodies (mAbs) have followed participants for up to 180 days, covering a typical single RSV season. However, to assess the full clinical impact of mAb administration, post-trial efficacy estimates are needed, particularly in countries where RSV circulation extends beyond six months. Methods: In this study, we applied a previously published Bayesian framework to estimate how the level of protective efficacy against RSV provided by clesrovimab and nirsevimab changes over the first year after administration. Using this Bayesian framework, which modeled new infections as Poisson processes with a Gaussian process prior for the force of infection and a parametric waning function for the intervention arm, we estimated placebo incidence rates and posterior waning functions. We validated our estimates by calculating model-estimated cumulative trial-period efficacy using an Incidence Rate Ratio (IRR) approach and by reconstructing event-free probability curves, comparing both with published clinical trial results. Results: Model-derived cumulative efficacy estimates closely matched trial-reported results for both products. The model-projected instantaneous probability of being protected at one year—an extrapolation beyond the observed trial follow-up—was 24.6% (95% CrI: 1.6–57.0%) for clesrovimab and 12.8% (95% CrI: 1.2–44.4%) for nirsevimab, with substantially overlapping credible intervals. Conclusions: Both RSV mAbs were projected to provide some level of protection throughout the first year following administration, with broadly similar levels of protection.

Read PDF

Similar papers

Review Open access Sep 2026

Clesrovimab, a monoclonal antibody for the prevention of respiratory syncytial virus disease in infants: a drug profile

Clesrovimab is a new medicine that helps protect babies against severe RSV disease and is currently very expensive, which means that it is not yet likely to be widely available through public healthcare systems in many low- and middle-income countries.

M. Wiedenmann, Z. Dangor, S. Madhi · 0 citations
Open access Sep 2026

Clinical and economic impact of bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccination in older adults: a cost-effectiveness analysis for Chile.

BACKGROUND Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract disease in older adults in Chile. Chile's National Immunization Technical Advisory Group (NITAG) recommended RSV vaccination for adults aged ≥60 years with risk factors for severe illness. This study estimated the cost-effectivenes...

Rafael Bolaños, Tomas Eduardo Abbott, A. Shajarizadeh et al. · 0 citations
Review Open access Oct 2026

Respiratory Syncytial Virus Vaccines: Who, When, and Which Vaccine? A Practical Guide for Clinicians

Respiratory syncytial virus (RSV) is a major cause of severe respiratory illness and hospitalization in older adults with chronic cardiopulmonary or metabolic conditions. After six decades without a preventive option, three RSV vaccines are now available: an adjuvanted prefusion F protein vaccine (Arexvy), a bivalent p...

Raeseok Lee · 0 citations

From Evidence to Implementation

Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory infections in young children. In 2019, RSV was estimated to cause approximately 33 million acute lower respiratory infections, 3.6 million hospitalisations and more than 101,000 deaths among children under five years of age, with more than...

N. Rave · 0 citations
Review Open access Sep 2026

Nirsevimab in the New Era of RSV Prevention: Current Evidence, Emerging Challenges, and Future Perspectives

Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infection (LRTI) and hospitalization in infants and young children worldwide, with the highest disease burden occurring in otherwise healthy term infants during the first 6 months of life. The recent introduction of long-acting monoclonal...

Marina Vasou, Rozeta Sokou, G. Kafalidis et al. · 0 citations
#protein folding Open access Oct 2026

RSV prefusion F vaccine effectiveness in older adults with immunosuppression: a prespecified analysis of the DAN-RSV trial.

In adults aged 60 years or older, RSVpreF vaccination reduced hospitalisations for RSV-related respiratory tract disease with no statistical evidence of effect modification by immunosuppression status; however, the study was not powered to exclude subgroup differences.

A. Reimer Jensen, M. H. Højbjerg Lassen, N. Johansen et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.